August 09, 2018 - Metabolix, Inc. (NASDAQ:YTEN) has filed a financial statement reporting Common Shares Outstanding of $10,011,395 USD. Previously, on May 10, 2018, Metabolix, Inc. reported Common Shares Outstanding of $9,968,455 USD. This represents a change of 0.43% in Common Shares Outstanding.

Period EndPeriodValue
2018-06-30 2018-Q2 10,011,395
2018-03-31 2018-Q1 9,968,455
2017-09-30 2017-Q3 3,461,714
2017-06-30 2017-Q2 2,879,550
2017-03-31 2017-Q1 28,498,560
2016-09-30 2016-Q3 28,342,625
2016-06-30 2016-Q2 27,844,260
2016-03-31 2016-Q1 27,369,390
2015-09-30 2015-Q3 27,331,435
2015-06-30 2015-Q2 26,981,214
2015-03-31 2015-Q1 135,540,088
2014-09-30 2014-Q3 135,182,140
2014-06-30 2014-Q2 35,094,640
2014-03-31 2014-Q1 34,993,744
2013-09-30 2013-Q3 34,581,449
2013-06-30 2013-Q2 34,516,762
2013-03-31 2013-Q1 34,446,953
2012-09-30 2012-Q3 34,306,570
2012-06-30 2012-Q2 34,196,756
2012-03-31 2012-Q1 34,191,853

Other Interesting Charts

Cost Of Revenue Research And Development Expenses - Costs And Expenses - Deferred Tax Assets Capitalized Research And Development Expenses - Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost - Effective Income Tax Rate Reconciliation Nondeductible Expense - Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost - Income Tax Expense Benefit - Increase Decrease In Deferred Revenue - Increase Decrease In Prepaid Deferred Expense And Other Assets - Operating Leases Rent Expense Net - Other Nonoperating Income Expense - Prepaid Expense And Other Assets Current - Revenue From Grants - Revenue From Related Parties - Revenue Product Sales To Related Party - Revenues - Sales Revenue Net - Selling General And Administrative Expense - Stock Offering Costs Remaining In Account Payable And Accrued Expenses -

Related News Stories

Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q2 2018 Results Earnings Conference Call August 9, 2018 4:30 PM ET (0-1)

Arcadia Biosciences:  A Speculative Pure-Play In The Genome Editing Agricultural Space

2018-07-16 seekingalpha
I highlight a number of reasons why I've taken a speculative position in RKDA, including commercialization prospects and cash on hand relative to historical burn rates. (5-3)

CUSIP: 591018809